Collectively, our results established FOXE1 as a critical tumor suppressor, regulating CRC cell growth and aerobic glycolysis through FOXE1/HK2 axis, which therefore could be a promising therapeutic target for CRC. Here, HK2 is linked to colorectal carcinoma.